Accordingly, the endoplasmic reticulum stress-inducing anticancer drug Bortezomib showed synergistic inhibition of ErbB2-overexpressing breast cancer cell proliferation when combined with ErbB2-targeted humanized antibody Trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.